Following the earlier introduction of Bretaris® (aclidinium), Menarini has released a new fixed-dose combination long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) bronchodilator in Brimica® Genuair® (aclidinium 340mcg/eformoterol 12mcg); a twice-daily maintenance treatment of moderate to severe stable chronic obstructive pulmonary disease (COPD).

Brimica® joins two other LAMA / LABA bronchodilators currently listed on the Pharmaceutical Benefits Scheme; Anoro®Ellipta® (vilanterol/umeclidinium) and Ultibro® Breezhaler® (indacaterol/glycopyrronium).

The dual mode of action of aclidinium and eformoterol target different pathways for optimal bronchodilation and reduces the number of inhalers patients need to use.

These combination products may delay the introduction of inhaled corticosteroid therapy in some moderate to severe COPD patients, thus reducing potential adverse effects such as oral candidiasis and pneumonia.

Brimica® Genuair® 340/12 is available as a streamline authority prescription under the Pharmaceutical Benefits Scheme for COPD patients who have stabilised with the combination of a LABA and a LAMA.


  1. Brimica® Genuair® 340/12 (aclidinium bromide/eformoterol dihydrate) Australian approved product information. Chatswood: A Menarini Australia Pty Ltd. Approved 1 May 2015.
  2. Yang I, Dabscheck E, George J, Jenkins S, McDonald C, McDonald V, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2015. Version 2.43. Milton: Lung Foundation Australia; 2015.
  3. Pharmaceutical Benefits Advisory Committee. Public Summary Document:
    ACLIDINIUM PLUS EFORMOTEROL dry powder inhaler, 340mcg plus 12mcg per actuation, 60 actuations, Brimica® Genuair®, A. Menarini Australia Pty Ltd – July 2015
    . Canberra: Australian Government Department of Health and Ageing; 2015.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates